Physician profile
Scott C Massios
NPI 1982681656
$5,827.37
in general payments reported to CMS, 2019-2025
22 companies · $1,262 in 2025
The $1,262 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $684 · 2021: $1,054 · 2022: $827 · 2023: $482 · 2024: $730 · 2025: $1,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,474.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,902.18 | 2019-2025 | Clareon, Unity, Ngenuity |
| Allergan, INC. | $487.66 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $463.43 | 2019-2021 | |
| Ivantis, INC | $348.74 | 2019-2021 | |
| Glaukos Corporation | $283.87 | 2019-2025 | Idosetr |
| Oyster Point Pharma, INC. | $256.48 | 2023-2025 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $180.52 | 2019-2025 | Tecnis Iol, Catalys System |
| Abbvie INC. | $173.22 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $105.52 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $96.20 | 2022-2025 | Vyzulta |
| Omeros Corporation | $91.02 | 2021 | |
| Rayner Intraocular Lenses Limited | $84.40 | 2023-2025 | Omidria, Rayone Aspheric, Rayone Emv |
| Harrow Eye, LLC | $73.92 | 2024-2025 | Vevye |
| Ocular Therapeutix, INC. | $68.47 | 2020-2023 | Dextenza |
| Eyepoint US, INC. | $61.07 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $32.95 | 2025 | Xdemvy |
| Astellas Pharma US INC | $29.44 | 2025 | Izervay |
| Sight Sciences, INC. | $26.20 | 2020 | |
| Sun Pharmaceutical Industries INC. | $17.91 | 2019 | |
| Shire North American Group INC | $15.56 | 2019 | |
| Rxsight INC | $14.39 | 2024 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Contact Lens |
| Biotissue Holdings INC. | $14.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Massios listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.